drugset / Trial / NCT00022737

Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia

NCT00022737

Phase 3 Completed 220 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well combination chemotherapy with or without donor peripheral stem cell transplant works in treating children with acute lymphoblastic leukemia. Giving combination chemotherapy before a donor peripheral stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.

Timeline

Start
2002-10
Primary completion
2006-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule Oral
Background Cyclophosphamide Other / unclassified Intravenous
Background Cyclosporine Peptide Intravenous
Background Cytarabine Small molecule Intravenous
Background Daunorubicin Small molecule Intravenous
Background Dexamethasone Small molecule Oral
Background Etoposide Small molecule Intravenous
Background Ifosfamide Small molecule Intravenous
Background Leucovorin Small molecule Intravenous
Background MERCAPTOPURINE ANHYDROUS Small molecule Oral
Background Methotrexate Small molecule Intrathecal
Background Pegaspargase Protein / enzyme biologic Intramuscular
Background Vincristine Small molecule Intravenous
Background asparaginase Protein / enzyme biologic Intramuscular
Background filgrastim Protein / enzyme biologic Subcutaneous